Clinical Trials Browser

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Phase 2 Active not recruiting

210 enrolled

Dermatologic

Uveal Melanoma

NCT05907954 2026-03-16

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2 Active not recruiting

160 enrolled

Dermatologic

Uveal Melanoma, Plaque, Amyloid

NCT07076550 2026-03-16

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Phase 1 Recruiting

50 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT07364474 2026-03-11

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Phase NA Recruiting

10 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04792463 2026-03-09

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Recruiting

500 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Cholangiocarcinoma

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT06246149 2026-03-04

ATOM

Phase 3 Recruiting

290 enrolled

Dermatologic

Uveal Melanoma

NCT04855435 2026-03-02

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Phase 1 Recruiting

106 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT06007690 2026-03-02

CoMpass

Phase 3 Recruiting

100 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Phase 2 Recruiting

44 enrolled

Dermatologic

Uveal Melanoma

NCT03417739 2026-02-25

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Phase 2 Terminated

13 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT06627244 2026-02-23

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Phase 2 Recruiting

30 enrolled

Dermatologic

Uveal Melanoma

NCT07421739 2026-02-19

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Recruiting

15 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT07015190 2026-02-18

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Phase 3 Recruiting

520 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT02517736 2026-02-17

O-Mel-Sora

Phase 2 Completed

32 enrolled

Dermatologic

Uveal Melanoma

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

420 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Phase 2 Completed

27 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT06432660 2026-02-06

PROMPT

Active not recruiting

42 enrolled

Dermatologic

Uveal Melanoma

NCT05607095 2026-02-04

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Phase 1 Recruiting

30 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04645680 2026-01-30

DIET

Phase 2 Active not recruiting

50 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT01983748 2026-01-28

Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

Phase 3 Completed

200 enrolled

Dermatologic

Uveal Melanoma

NCT03865212 2026-01-28

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Phase 1 Terminated

12 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT06717126 2026-01-16

OCULE-01

Phase 2 Active not recruiting

85 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT07338968 2026-01-14

CoMpass

Not yet recruiting

100 enrolled

Dermatologic

Uveal Melanoma

NCT03746431 2026-01-07

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Phase 1 Terminated

78 enrolled

BreastDermatologicEndocrineGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Phase 1 Active not recruiting

352 enrolled

DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

Clinical Trials

PROQEM

Neoadjuvant Tebentafusp for Uveal Melanoma

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

ACTengine

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

iSITE

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Psychoeducation for Uveal Melanoma

IGCMU

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

PALANGI3

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

ATOM

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

CoMpass

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Neoadjuvant Darovasertib in Primary Uveal Melanoma

O-Mel-Sora

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

PROMPT

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

DIET

Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

OCULE-01

CoMpass

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors